M PATRICK PERIN

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

• L'archéologie des Wisigoths en Gaule au V e siècle

  2025

  Chapitre

• La datation de la tombe de la reine Arégonde, belle-fille de Clovis. Au carrefour de l’archéologie, de l’anthropologie et de l’histoire

  2024

  CongrèsDatations « absolues » en archéologie : 8e séminaire scientifique et technique de l’Inrap

• The Grave of King Childeric I († 481/482).

  2022

  Chapitre

• Bead and Garnet Trade between the Merovingian, Mediterranean, and Indian Worlds

  2020

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

  Respiratory research · 2016

  📚 80 citations🎯 RCR 2.87Top 17% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗
• 2

  Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial

  Open forum infectious diseases · 2022

  📚 17 citations🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  Abstract Background Tocilizumab, an interleukin 6 receptor (IL-6R) antagonist monoclonal antibody, has shown efficacy in patients with coronavirus disease 2019 (COVID-19) pneumonia, but the optimal dose is unknown. Methods Patients hospitalized for moderate to severe COVID-19 pneumonia were randomized 1:1 to receive standard of care treatment and 1–2 doses of intravenous tocilizumab 4 mg/kg or 8 mg/kg (open-label). Primary pharmacokinetic and pharmacodynamic end points were serum concentrations of tocilizumab and soluble interleukin 6 receptor (sIL-6R), IL-6, ferritin, and C-reactive protein (CRP), from baseline to day 60. The secondary end point was safety. Key exploratory efficacy end points included clinical status, time to discharge, mortality rate, and incidence of mechanical ventilation. Results Of 100 patients randomized, 49 received tocilizumab 4 mg/kg and 48 received 8 mg/kg. In pharmacokinetic and sIL-6R assessments, dose-dependent differences were seen in patients who received 1 or 2 doses of 4 or 8 mg/kg. Serum concentrations of IL-6, ferritin, and CRP and safety outcomes were comparable between groups. Through day 60, serious adverse events were reported in 30.6% and 25.0% of patients in the 4- and 8-mg/kg groups, respectively. Eight patients (16.3%) in the 4-mg/kg group and 6 (12.5%) in the 8-mg/kg group died. Exploratory time-to-event outcomes favored 8 mg/kg within the first 2 weeks. Conclusions In patients with moderate to severe COVID-19 pneumonia who received tocilizumab 4 or 8 mg/kg, pharmacokinetic and sIL-6R assessments showed expected dose-dependent effects; pharmacodynamic assessments and safety were comparable, with no new safety signals. Further study is required before a lower dose of tocilizumab can be recommended in patients with COVID-19 pneumonia. Clinical Trials Registration NCT04363736.

Publications scientifiques (3) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• GRD_HMA_GES_52313_0001_0002

  Image2023NAKALA - https://nakala.fr (Huma-Num - CNRS)

  Source: Provins, Archives départementales de Seine-et-Marne, Fonds Gilbert-Robert Delahaye

• Additional file 3: Table S2. of A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

  Dataset2016Figshare

  FEV1 at Week 36 (all patients and biomarker subgroups). (XLSX 48Â kb)

• 93, Saint-Denis, Basilique, plans du secteur

  Book2021NAKALA - https://nakala.fr (Huma-Num - CNRS)

• GRD_HMA_GES_52527_0001_0003

Partager cette fiche